NPP-2-21

NPP-2-21 is a rationally engineered small-molecule prodrug designed to selectively inhibit ubiquitin-activating enzyme 1 (UBA1), the primary E1 enzyme at the apex of the ubiquitin-proteasome system (UPS). Developed as a next-generation UBA1 inhibitor to overcome the limitations of first-in-class agents like TAK-243, NPP-2-21 is inactive in vitro but undergoes efficient in vivo conversion to an active UBA1-inhibitory metabolite. This prodrug strategy enhances systemic stability and exposure, leading to a significantly higher maximum tolerated dose and improved pharmacokinetic/pharmacodynamic profiles compared to first-generation inhibitors. In preclinical studies, NPP-2-21 has demonstrated potent antitumor efficacy across various cancer models, both as a monotherapy and in synergy with immune checkpoint blockade, while maintaining high selectivity for UBA1 over other E1 enzymes. It is also compatible with liposomal formulations, which may allow for reduced dosing frequency in clinical settings.